Scinai director reports initial share holdings

Scinai Immunotherapeutics Ltd. director Yael Margolin filed an initial ownership report showing existing equity interests rather than new trades.

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. director Yael Margolin filed an initial ownership report showing existing equity interests rather than new trades. Margolin directly holds 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares and have no expiration date.

In addition, Margolin holds stock options over 1,720,000 and 8,000,000 Ordinary Shares at an exercise price of $0.0050 per share, expiring on August 24, 2033, and options over 48,200,000 Ordinary Shares at an exercise price of $0.0004 per share, expiring on December 22, 2035. These options vest in annual installments beginning on August 24, 2024, August 24, 2027, and December 22, 2026, subject to continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider MARGOLIN YAEL

Role Director

Type	Security	Shares	Price	Value
holding	American Depositary Shares	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: American Depositary Shares — 200,000 contracts (Direct); Stock Option (right to buy) — 57,920,000 contracts (Direct)

Footnotes (5)

1. F1. Represents 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares, at the holder's election and have no expiration date.
2. F2. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.
3. F3. The option vests in one installment on August 24, 2027, subject to the Reporting Person's continued service through such date.
4. F4. The option vests in three equal annual installments commencing August 24, 2024, subject to the Reporting Person's continued service through such dates.
5. F5. The option vests in three equal annual installments commencing December 22, 2026, subject to the Reporting Person's continued service through such dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing show for Scinai Immunotherapeutics (SCNI) director Yael Margolin?

The Form 3 shows Yael Margolin’s existing ownership in Scinai Immunotherapeutics. It reports holdings of American Depositary Shares and multiple stock option grants over Ordinary Shares, establishing her baseline equity position as a director without indicating any new purchases or sales.

How many Scinai Immunotherapeutics (SCNI) shares does Yael Margolin’s ADS position represent?

Margolin holds 50 American Depositary Shares, which are convertible into 200,000 Ordinary Shares. The ADSs are convertible at the holder’s election and have no expiration date, giving her ongoing flexibility to convert into Ordinary Shares if and when desired.

What stock options over Ordinary Shares does Yael Margolin hold in Scinai Immunotherapeutics (SCNI)?

Margolin holds options over 1,720,000 and 8,000,000 Ordinary Shares with a $0.0050 exercise price, plus options over 48,200,000 Ordinary Shares at $0.0004. These options have long-dated expirations in 2033 and 2035, providing significant potential future equity exposure.

When do Yael Margolin’s Scinai Immunotherapeutics (SCNI) stock options vest?

One option grant vests in a single installment on August 24, 2027. Other grants vest in three equal annual installments starting on August 24, 2024 and December 22, 2026, in each case conditioned on Margolin’s continued service with the company.

Did Yael Margolin buy or sell Scinai Immunotherapeutics (SCNI) shares in this Form 3 filing?

The Form 3 does not report any new purchases or sales of securities. It is an initial ownership statement that lists Margolin’s existing American Depositary Shares and stock option positions, rather than documenting open-market transactions or option exercises.

What are the expiration dates of Yael Margolin’s Scinai Immunotherapeutics (SCNI) stock options?

Margolin’s options over 1,720,000 and 8,000,000 Ordinary Shares expire on August 24, 2033. Her options over 48,200,000 Ordinary Shares expire on December 22, 2035, giving her a long time horizon to potentially exercise these rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 10:08 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MARGOLIN YAEL

(Last) (First) (Middle)

C/O SCINAI IMMUNOTHERAPEUTICS LTD.

JERUSALEM BIOPARK, 2ND FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Scinai Immunotherapeutics Ltd. [ SCNI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(1)	(1)	Ordinary shares, no par value per share ("Ordinary Shares")(2)	200,000	(1)	D
Stock Option (right to buy)	(3)	08/24/2033	Ordinary Shares	1,720,000	$0.005	D
Stock Option (right to buy)	(4)	08/24/2033	Ordinary Shares	8,000,000	$0.005	D
Stock Option (right to buy)	(5)	12/22/2035	Ordinary Shares	48,200,000	$0.0004	D

Explanation of Responses:

1. Represents 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares, at the holder's election and have no expiration date.

2. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

3. The option vests in one installment on August 24, 2027, subject to the Reporting Person's continued service through such date.

4. The option vests in three equal annual installments commencing August 24, 2024, subject to the Reporting Person's continued service through such dates.

5. The option vests in three equal annual installments commencing December 22, 2026, subject to the Reporting Person's continued service through such dates.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Amir Reichman, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)